Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...

ORLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective ...

Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GLP-1 receptor agonist therapy reduced surgical abscess repairs and hospitalizations among people with hidradenitis ...

USA: A retrospective comparative effectiveness study among veterans with type 2 diabetes found that three GLP-1 receptor ...

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...